Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I've been looking through related RNS for any mention of a 'get out' clause re handing/taking back 737 but don't see anything. Could this play into the hands of Sierra e.g. as there's no deadline for progress we're not giving it back yet so if you want it now then cough up?
Clearly a RNS wouldn't go into the minutiae of the contract but does anyone know if there was a deadline for progress clause?
Yep exactly....the perfect drug for the combo ....the pharmaceutical version of romeo and juliet......just hope like the story does not lead to tragic loss of life because of Sierra arrogance and ineptitude
In my opinion AZN must be climbing all over the back of Sierra, closely followed by the ICR
Hi Num4. Delay tactics but the bucket load. They have cut funds from SRA737 research to fund Momoletonib. Sooner or later I feel that need to 5 hit or get off the pot.
Regards.
The TP53 mutation in various cancers makes our CHK1 extremely valuable. Sierra are Micky Mouse really, previously called Pro-NAI, had some dodgy dealings under that name - they moved fast with SRA737 at the start but handbrake was then applied as they bit off more than they can chew and they didn't have the financial backing to progress it.
CPF partnered wrongly IMO but who knows what promises were made that they have failed to deliver on.
Time is of the essence for all these sufferers, Sierra legacy proving to be delay delay delusional.
Damion. The link you have shown is from 2017. Since then CHK1 research has moved on 4 years. Perhaps you could also enlighten us on what other combos with 'our Chk1' previously presented at the AACR and have amounted to nothing.
With regards to Momelotinib, in Sierra report( much more recent than 2017 I might add) it has been stated that SRA737 may prove to be more commercially viable then Momelotinib.
With the SRA 737 removed from the SRA737 website ( ie not for sale) I can only deduce that SRA737 is worth considerably more than what some people here think.
Regards
The momo drug does nothing amazing in my book.....do you really think that a company many times the size of Sierra with best scientists that found it and done research and decided not fir them and then sold it for peanuts and then bought back in after a while ....
If this was my company and I give amazing drug away for peanuts ,would expect some big questions answered .
There are so many challenges and complexities where combination drugs are involved itâs not a simple process: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415086/
There have been many combinations for ours and other CHK1âs previously presented at AACR that amounted to nothing look at the Janssen combo that was pulled after all the pre clinical and CTA!
Still not expecting anything from Sierra if they donât manage to on license and ultimately return SRA737 they will still pull some hefty royalties if itâs commercialised in the future. I think some here donât realise the commercial value of Momelotinib or its P3 endpoints for its fast track thatâs why they are 100% focused on Momelotinib.
Hi All
Something doesnât stack up here. When NG was CEO we had already looked at combos (must be 2018 or earlier), at the time the trials were going âgangbustersâ (for which we are still to see the formal results, read outs and endpoints). Then NG went nuts on his speculative acquisition of the momly thing, got fired and Dilly took over. During this time and since they have stopped all trials (reported saving over $5m in trial costs) diluted and renegotiated the original license agreement, had some significant directors buying and some decent rise in the sp.
IMHO, the renegotiated agreement has a ânewâ time clause for returning the compound and it looks like ICR are cranking up pressure to get moving. I recall Tim stating that the revised agreement should see the compound recommence âin a timely mannerâ
If its returned because Sierra canât afford to commence or fail to on license then it will cost Sierra dearly and probably see their demise. There is so much going on in the background and it must be close to revealing soon.
GLA
That should read, in the USA in 2021.
In the USA, where Sierra are based, it is estimated that 21,000 women will receive a diagnoses of ovarian cancer and that 13,718 women will die from that cancer. That is a very high percentage of deaths, 64% or almost two thirds. The case for going into human trials seems overwhelming. One has to ask why Sierra are so slow to move on this indication.
The results from the the AACR conference for the combo look very impressive on the chart. Its time for less deep thinking and more deep pockets from Dilly & the potential license partner. If not forthcoming soon, time to return to mother ship to be properly progressed.
Iâm sure what Krone was saying probably fits the bill, saying that Dilly said they had a nice Chk1 in their back pocket, Not the front pocket!
When they are ready too do something with it they will, and will be able too see that from a trial application Krone would usually find something and this site is always ahead of itself with this or that is happening, havenât seen a clear sign yet but the 6-7% fund is a sign maybe, but something more conclusive would be better!
Hmmmm, if it were to be transferred to another owner then I doubt we'll see anything from Sareum tomorrow as I expect we'd have to await an official announcement from Sierra/A N Other.
Perhaps there might be a co-ordinated announcement later in the week. Wishful thinking?
Whilst no direct link to SRA737 on Sierra website and not even on their pipeline page although it is clearly in trials and awaiting results.
https://www.sierraoncology.com/science/#pipeline
Why would a company that has the rights to a drug not include it in the pipeline page, only 2 reasons I can think of, it is going to be discontinued and they try and hide the failure (contradicts the research and drive ICR have for this) or the compound is being transferred to a new owner? Which is what we are all hoping for.
They do have a hidden page on chk1 still live but unsure on dates of this publication and potentially just missed from the cleanup, google finds it, and to get it on the structured page with regards to SEO you have to select as a cornerstone page (if I remember rightly, been a while. )
Should be a good week for Sareum, our chairman has already retweeted Udai's tweet - however, I'd like to see them make comment and not just press a button.
Royalties on this could really transform Sareum. Looking forward to the next Q&A
https://www.sierraoncology.com/chk1/